Clinical trial · no report yet · Phase 1

NCT06736327

A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors

NCT06736327 ↗
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Focused

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

Channel	Found
X threads	3

The trial

ClinicalTrials.gov

Official title: A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 for Injection in Subjects With Advanced Solid Tumors
Phase: Phase 1
Status: Recruiting
Conditions: Advanced Solid Tumors
Interventions: SKB500
Arms: SKB500 · Experimental
Enrollment: 180 (estimated)
Primary outcomes: Evaluate the incidence of adverse events (AEs)
Evaluate the incidence of serious adverse events (SAEs)
Evaluate the incidence of treatment related adverse events (TRAEs)
Evaluate the incidence of dose-limiting toxicities (DLTs)
Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Start: Dec 13, 2024
Primary completion: Jul 31, 2027 (estimated)
Results posted: No
Registry record: NCT06736327 · updated May 8, 2026